Name: PAVMED INC (PAVM) Stock
Brand: PAVMED INC
Rating: 4 (3 reviews)

PAVM Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

13 days ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

13 days ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

a month ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

a month ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

a month ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

2 months ago - By: Zacks Investment Research

PAVmed (PAVM) Upgraded to Strong Buy: Here's Why

7 months ago - By: Benzinga

PAVmed's Earnings: A Preview

13 days ago - By: Benzinga - Mentions: ECC VINP INV VTGN ...

Earnings Scheduled For November 13, 2025

2 months ago - By: PAVmed Inc.

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

2 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

3 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

3 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

3 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

3 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

3 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

3 months ago - By: The Motley Fool

PAVmed Revenue Jumps 513% in Q2

4 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

4 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

4 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

4 months ago - By: Lucid Diagnostics - Mentions: LUCD

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

5 months ago - By: PAVmed Inc.

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

5 months ago - By: Lucid Diagnostics - Mentions: LUCD

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

6 months ago - By: PAVmed Inc.

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

6 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

7 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

7 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

7 months ago - By: PAVmed Inc. - Mentions: LUCD

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

7 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

7 months ago - By: Zacks Investment Research

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

7 months ago - By: Lucid Diagnostics - Mentions: LUCD

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

8 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

8 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

8 months ago - By: Lucid Diagnostics - Mentions: LUCD

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

8 months ago - By: Lucid Diagnostics - Mentions: LUCD

PAVMED INC (PAVM) Stock News

PAVM Latest News, Press Relases and Analysis

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit

PAVmed (PAVM) Upgraded to Strong Buy: Here's Why

PAVmed's Earnings: A Preview

Earnings Scheduled For November 13, 2025

PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025

PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology

PAVmed Revenue Jumps 513% in Q2

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test

PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results

Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results

PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025

PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know

NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference